Integration of clinical and blood parameters in risk prognostication for patients receiving immunochemotherapy for extensive stage small cell lung cancer: real-world data from two centers
Open Access
- 11 September 2024
- journal article
- research article
- Published by Springer Nature in BMC Medicine
- Vol. 22 (1) , 1-15
Abstract
Immune checkpoint inhibitors (ICIs) had modest advances in the treatment of extensive-stage small cell lung cancer (ES-SCLC) in clinical trials, but there is a lack of biomarkers for prognosis in clinical practice. We retrospectively collected data from ES-SCLC patients who received ICIs combined chemotherapy from two centers in China, integrated clinical and blood parameters, and constructed risk prognostication for immunochemotherapy. The population was divided into high- and low-risk groups, and the performance of the model was assessed separately in the training and validation cohorts. Two hundred and twenty and 43 patients were included in the training and validation groups, respectively. The important predictors were screened including body mass index, liver metastases, coefficient variation of red blood cell distribution width, lactate dehydrogenase, albumin, and C-reactive protein. Predicting 1-year overall survival (OS), the AUC values under ROC for the model under training, internal validation, and external validation were 0.760, 0.732, and 0.722, respectively, and the calibration curve and clinical decision curve performed well. Applied the model to divide patients into low-risk and high-risk groups, and the median OS was 23.7 months and 9.1 months, and the median progression-free survival was 8.2 months and 4.8 months, respectively; furthermore, this ability to discriminate survival was also observed in the validation cohort. We constructed a novel prognostic model for ES-SCLC to predict survival employing baseline tumor burden, nutritional and inflammatory parameters, it is easily measured to screen high-risk patient populations.Keywords
Funding Information
- Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park (Z211100002921013)
- Tongzhou Lianggao Talents Project (YH201920)
- Beijing Municipal Public Welfare Development and Reform Pilot Project for Medical Research Institutes (JYY2023-15)
This publication has 52 references indexed in Scilit:
- Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLCCancer Immunology Research, 2017
- Prognostic significance of serum LDH in small cell lung cancer: A systematic review with meta-analysisCancer Biomarkers, 2016
- Small cell lung cancer: Where do we go from here?Cancer, 2014
- Red blood cell distribution width: A simple parameter with multiple clinical applicationsCritical Reviews in Clinical Laboratory Sciences, 2014
- Increased Red Blood Cell Distribution Width Associates with Cancer Stage and Prognosis in Patients with Lung CancerPLOS ONE, 2013
- The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancerCancer Treatment Reviews, 2013
- Specific organ metastases and survival in small cell lung cancerOncology Letters, 2012
- Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosisThe American Journal of Clinical Nutrition, 2006
- Inflammatory chemokines in cancer growth and progressionEuropean Journal of Cancer, 2006
- Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer—what limits limited disease?Lung Cancer, 2002